Jiaxuan Chen

Based at Harvard University, Jiaxuan Chen focuses their scholarly efforts on Vitamin D immunology, cancer immunology, nucleic acid delivery, autoimmune disease mechanisms, gut microbiota, protein nanoparticles, exosome biology, computational biology, bridging the gap between theory and practice in Vitamin D immunology. A representative example of their recent contribution is the study titled "A novel peptide 66CTG stabilizes Myc proto-oncogene protein to promote triple-negative breast cancer growth", which offers critical insights into the dynamics of Vitamin D immunology and cancer immunology. Additional work such as "Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort" further demonstrates their commitment to advancing knowledge in this domain.